000088292 001__ 88292
000088292 005__ 20250114155357.0
000088292 0247_ $$2doi$$a10.3390/jcm8122209
000088292 0248_ $$2sideral$$a116468
000088292 037__ $$aART-2019-116468
000088292 041__ $$aeng
000088292 100__ $$aMarco-Benedi, Victoria
000088292 245__ $$aAortic valvular disease in elderly subjects with heterozygous familial hypercholesterolemia: impact of lipid-lowering therapy
000088292 260__ $$c2019
000088292 5060_ $$aAccess copy available to the general public$$fUnrestricted
000088292 5203_ $$aHypercholesterolemia and statins are risk factors for aortic stenosis (AS) and vascular calcification, respectively. Whether heterozygous subjects with familial hypercholesterolemia (HeFH) treated with statins are at risk of AS is unknown. We study the prevalence of AS, aortic valve calcification (AoVC), and aortic sclerosis (ASc) in elderly subjects with HeFH in a prolonged statin treatment. Case-control study, cases were adults >= 65 years of age with a genetic diagnosis of HeFH, LDLc >220 mg/dl, and statin treatment >= 5 years. Controls were relatives of HeFH patients, with LDLc <190 mg/dl. Participants underwent a cardiac ultrasound for aortic valve analysis. We studied 205 subjects, 112 HeFH and 93 controls, with mean age 71.8(6.5) years and 70.0(7.3) years, respectively. HeHF, with respect to controls, presented greater gradients of aortic transvalvular pressure, 7.4(7.3) mmHg versus 5.0(2.8) mmHg, and maximum aortic velocity, 1.7(0.7) m/s versus 1.5(0.4) m/s, and lower aortic valve opening area, 2.0(0.7) cm(2) versus 2.4(0.6) cm(2) (all p < 0.05). AoVC and ASc were also more prevalent in HeFH (p < 0.05 between groups). Moderate/severe AS prevalence was higher among HeFH: 7.1% versus 1.1% (age- and sex-adjusted odds ratio (OR) 8.33, p = 0.03). Independent risk factors for aortic valve disease in HeFH were age and LDLc before treatment. The number of years under statin treatment was not associated with any aortic valve measurement. Subjects >= 65 years with HeFH in prolonged statin treatment show more aortic valvular disease and higher frequency of AS than controls. Life-long elevated LDLc exposure, rather than time of exposure to statins, explains this higher risk.
000088292 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/PI15-01983
000088292 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000088292 590__ $$a3.303$$b2019
000088292 591__ $$aMEDICINE, GENERAL & INTERNAL$$b36 / 165 = 0.218$$c2019$$dQ1$$eT1
000088292 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000088292 700__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, Martín
000088292 700__ $$aCasado-Domínguez, Juan M.
000088292 700__ $$aVilla-Pobo, Rosa
000088292 700__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, Rocío$$uUniversidad de Zaragoza
000088292 700__ $$aSánchez-Hernández, Rosa M.
000088292 700__ $$aBlanco Nuez, Marta
000088292 700__ $$aOrtega-Martínez de Victoria, Emilio
000088292 700__ $$aSitges, Marta
000088292 700__ $$aPedro-Botet, Juan
000088292 700__ $$0(orcid)0000-0002-1309-4363$$aPuzo, José$$uUniversidad de Zaragoza
000088292 700__ $$aVillarroel, Teresa
000088292 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, Fernando$$uUniversidad de Zaragoza
000088292 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000088292 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000088292 773__ $$g8, 12 (2019), 2209 [13 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000088292 8564_ $$s899323$$uhttps://zaguan.unizar.es/record/88292/files/texto_completo.pdf$$yVersión publicada
000088292 8564_ $$s474977$$uhttps://zaguan.unizar.es/record/88292/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000088292 909CO $$ooai:zaguan.unizar.es:88292$$particulos$$pdriver
000088292 951__ $$a2025-01-14-15:51:53
000088292 980__ $$aARTICLE